Regen BioPharma Inc. is seeking U.S. patent protection for a method to use T cells when treating solid tumors.
The company filed a utility patent application with the U.S. Patents and Trademark Office for killing solid tumors using NR2F6-silenced CAR T cells.
"By activating the adaptive arm of the immune system, in the form of NR2F6-silenced T cells, we anticipate achieving synergistic effects in killing of solid tumors, something which has not been observed in previous CAR-T approaches," Regen BioPharma President and Chief Scientific Officer Harry Lander said.